Rohit Bhalla, DO
Infectious Disease · Hillsborough, NJNPI 1962604819
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 346 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Gilead at 25.0% of the total.
Across 346 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Organogenesis Inc.$2K
- Viiv Healthcare Company$941
- Merck$586
- Insmed, Inc.$403
- Paratek Pharmaceuticals, Inc.$281
- plus $2K from 24 others
What the payments were for
- Food & beverage$7,08596%
- Education$2944%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 97 | $1,845 |
| Organogenesis Inc. | 36 | $1,538 |
| Viiv Healthcare Company | 60 | $941 |
| Merck | 40 | $586 |
| Insmed, Inc. | 17 | $403 |
| Paratek Pharmaceuticals, Inc. | 14 | $281 |
| AbbVie(2 entities) | 11 | $265 |
| Aimmune Therapeutics, Inc. | 13 | $216 |
| Urgo Medical North America, LLC | 2 | $198 |
| Smith+Nephew | 12 | $183 |
| Johnson & Johnson | 9 | $140 |
| La Jolla Pharmaceutical Company | 3 | $111 |
| Janssen Products, LP | 1 | $99 |
| Shionogi Inc | 5 | $87 |
| Vertos Medical, Inc. | 1 | $75 |
| Theratechnologies Inc. | 5 | $75 |
| Novo Nordisk | 5 | $71 |
| Grifols USA, LLC | 2 | $36 |
| Ferring Pharmaceuticals Inc. | 2 | $30 |
| Tactile Systems Technology Inc | 1 | $26 |
| Molnlycke Health Care US, LLC | 1 | $25 |
| Hydrofera LLC | 1 | $24 |
| Solventum Corporation | 1 | $23 |
| Pfizer | 1 | $17 |
| Kerecis Limited | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Integra Lifesciences Corporation | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PuraPly$508
- UrgoK2$170
- VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP$170
- Apligraf$166
- Affinity$124
- Puraply Antimicrobial$122
- APRETUDE$122
- DALVANCE$119
- Biktarvy$104
- NUZYRA$103
How this compares
$7,379 in reported general payments places this provider in the 85th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 12 | $285,179 |
| JulucaDolutegravir/Rilpivirine | 15 | $53,906 |
| DovatoDolutegravir Sodium/Lamivudine | 15 | $50,169 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $49,877 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 14 | $48,692 |
| Methenamine Hippurate | 25 | $2,202 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 28 | $1,681 |
| Doxycycline Hyclate | 49 | $1,272 |
| Rifampin | 15 | $912 |
| Vancomycin Hcl | 11 | $911 |
| CeftriaxoneCeftriaxone Sodium | 17 | $486 |
| Cefadroxil | 27 | $448 |
| Amoxicillin | 13 | $159 |
| Isoniazid | 15 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Biktarvy | $1,845 | $335,05624 claims |
| Viiv Healthcare CompanyJuluca, Dovato, Triumeq | $941 | $152,76744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 334 infectious disease providers in New Jersey.
Other infectious disease in Hillsborough
- Ronald NahassHillsborough$213K
- Robert SegalHillsborough$41K
- Jerry SheenHillsborough$6K
- Meena SeenivasanHillsborough$6K
- David HermanHillsborough$4K
- Nazar RaoofHillsborough$4K
- Keith GottesdienerRahway$2.1M
- Jihad SlimNewark$2.1M
- Maria SzabelaNewark$474K
- Christopher LucastiSomers Point$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.